KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in TaxesDivestmentsDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and Equipment
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Amortization (2016 - 2025)

Historic Amortization for Gsk (GSK) over the last 17 years, with Q4 2025 value amounting to $595.9 million.

  • Gsk's Amortization fell 8426.83% to $595.9 million in Q4 2025 from the same period last year, while for Dec 2025 it was $11.0 billion, marking a year-over-year increase of 6022.29%. This contributed to the annual value of $4.2 billion for FY2025, which is 277.7% down from last year.
  • Gsk's Amortization amounted to $595.9 million in Q4 2025, which was down 8426.83% from $2.9 billion recorded in Q3 2025.
  • Over the past 5 years, Gsk's Amortization peaked at $18.3 billion during Q4 2022, and registered a low of $84.5 million during Q3 2024.
  • Moreover, its 5-year median value for Amortization was $2.2 billion (2021), whereas its average is $3.9 billion.
  • Its Amortization has fluctuated over the past 5 years, first plummeted by 9565.36% in 2024, then soared by 332475.32% in 2025.
  • Gsk's Amortization (Quarter) stood at $6.9 billion in 2021, then surged by 166.72% to $18.3 billion in 2022, then plummeted by 64.04% to $6.6 billion in 2023, then crashed by 42.51% to $3.8 billion in 2024, then crashed by 84.27% to $595.9 million in 2025.
  • Its Amortization was $595.9 million in Q4 2025, compared to $2.9 billion in Q3 2025 and $2.2 billion in Q2 2025.